Pharmaceutical / Drug Definition :
Inhibits conversion of angiotensin I to the vasoconstrictor angiotensin II, inactivates bradykinin and other vasodilatory prostaglandins, increases plasma renin levels, and reduces aldosterone levels. Net effect is systemic vasodilation.
FDA Label Requirements and Exceptions
Moexipril Hydrochloride
FDA Import Information
Moexipril Hydrochloride
FDA Detentions
Moexipril Hydrochloride (Moexipril Hydrochloride Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Moexipril Hydrochloride (Moexipril Hydrochloride Suppliers)
- Processors Moexipril Hydrochloride
- Repackers Moexipril Hydrochloride
- Relabelers Moexipril Hydrochloride
- Exporters Moexipril Hydrochloride
- Importers Moexipril Hydrochloride
For more information about Moexipril Hydrochloride, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.
